The UK and US have secured a key trade agreement that will ensure zero duties on British drug shipments entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to raise expenditure on drugs through the public health system. This commitment ensures that duties on these crucial exports will remain at nothing for a period of 36 months.
This agreement comes after previous statements to hike duties on branded pharmaceutical products, with figures mentioned reaching one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and brings long-overdue equity to transatlantic pharmaceutical trade," a release noted.
Trade Significance
Drugs represent one of the the United Kingdom's biggest goods shipped to the US, which is easily the largest destination for leading UK drugmakers.
Statistics reveal that in the one-year period leading up to September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that period.
"This deal protects employment, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Detailed UK Commitments
The deal entails several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to raise total public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
This agreement takes place against a protracted tension between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by arguments that American customers were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the last ten years.
